Report
Martial Descoutures ...
  • Oussema Denguir

Erytec Pharma : Update on phase II of Investigator Sponsored Trial in ALL

>Finalisation of patient enrolment and encouraging initial results - This morning, Erytech provide an update on phase II of the trial sponsored by the Nordic Society of Paediatric Haematology and Oncology (NOPHO). It is evaluating eryaspase in primarily paediatric acute lymphoblastic leukaemia (ALL) patients who developed hypersensitivity reactions to pegylated asparaginase. The recruitment of 50 patients has been finalised. Without providing any numbers, Erytech ann...
Underlying
PHAXIAM THERAPEUTICS

Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Martial Descoutures

Oussema Denguir

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch